Three Companies Control 80% of the Prescription Market. AlignRx Built a Public Benefit LLC to Push Back, and Tells the Story on "All Access with Andy Garcia"

Three pharmacy benefit managers—CVS Caremark, Optum Rx and Express Scripts—processed roughly 80% of U.S. prescription claims last year, according to AlignRx, highlighting concentration in pharmacy reimbursement. AlignRx, a public-benefit PSAO representing nearly 5,300 community pharmacies, says reimbursements can fall below drug acquisition costs and that consolidation is contributing to pharmacy closures and care gaps, particularly in Medicaid- and Medicare-heavy communities. The announcement promotes an upcoming public-television documentary advocating for greater reimbursement transparency, competition and patient pharmacy choice.

Analysis

The investable issue is not the media exposure but whether it adds momentum to state and federal PBM reform that constrains spread pricing, reimbursement discretion, and pharmacy-network steering. CVS has the most direct public-equity exposure through Caremark, but its integrated model also makes earnings sensitivity difficult to isolate: lower PBM economics could be partly offset by greater retail prescription retention or insurance-member value. The asymmetric risk is multiple compression rather than an immediate earnings reset, as investors may apply a higher regulatory discount to vertically integrated healthcare platforms before any rule has a quantified P&L impact.

Over 1-3 months, monitor state legislative calendars, FTC/PBM enforcement developments, and employer-plan contract language for movement toward pass-through pricing, fiduciary standards, or limits on affiliated-pharmacy steering. Those changes would disproportionately pressure CVS, UNH and Cigna (CI), while improving survival odds for independent pharmacies and potentially supporting drug wholesalers McKesson (MCK) and Cardinal Health (CAH) through a more durable independent-customer base. The contrarian view is that public scrutiny is already well understood and fragmented state action may raise compliance costs without materially impairing PBM purchasing leverage; absent a federal remedy or a visible Caremark guidance cut, this is not sufficient standalone evidence for a new directional CVS short.

Key Decisions for Investors

• Maintain a regulatory-risk watch on CVS rather than initiating a news-driven short; escalate only if CVS discloses PBM pricing/rebate pressure, narrows Caremark margin guidance, or faces an adverse federal enforcement milestone. A guidance reduction would be the cleaner 1-3 month catalyst than advocacy-driven headlines.
• For existing CVS longs, consider a 3-6 month downside hedge via CVS put spreads around earnings or major PBM-policy events; the thesis is valuation de-rating from regulatory uncertainty, while the hedge should be removed if management reaffirms PBM profitability and regulatory proposals fail to advance.
• Screen MCK and CAH for evidence that independent-pharmacy closures are moderating and generic-volume growth is accelerating; only then consider a 6-18 month relative long versus CVS. The trade requires confirmation that improved pharmacy economics translate into retained wholesale volumes, not merely lower PBM reimbursements.
• Use a sector pair only after a concrete policy catalyst: long MCK/CAH versus short CVS in equal beta-weighted exposure. Falsify the pair if reform preserves PBM administrative-fee economics, CVS demonstrates retail-share gains that offset Caremark pressure, or wholesaler operating margins fail to improve.